# Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion

- Link: https://www.thailand-business-news.com/pr-news/innogen-pharmaceuticals-enters-into-licensing-agreement-with-arcera-life-sciences-for-efsubaglutide-alfa-accelerating-international-expansion
- Published: 2026-11-19T17:05:00+07:00
- Author: PR Newswire

◦ _Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa
   in selected countries in Africa, Latin America, the Middle East and Eastern Europe,
   while Innogen retains the relevant rights in the rest of the world._
 ◦ _Under the agreement, Innogen will receive US$38 million in upfront and near-
   term milestone payments, including a non-refundable upfront payment of US$15 
   million, as well as sales milestone payments and tiered royalties at rates of
   up to double-digit percentage based on aggregate annual net sales of the Product
   in the Territory. The total potential deal value is over US$1 billion._
 ◦ _The collaboration marks an important step in bringing a China-developed and 
   commercialized innovative GLP-1 therapy to international markets and will further
   advance Innogen’s global strategy._

HONG KONG and ABU DHABI, UAE, Nov. 19, 2026 /PRNewswire/ — Innogen Pharmaceuticals("
Innogen", HKEX: 2591) today announced that it has entered into an exclusive licensing
and commercialization agreement with Arcera Life Sciences Ltd. ("Arcera") for the
development and commercialization of its internally developed innovative product
Efsubaglutide Alfa, in international markets.

The collaboration represents an important milestone in the international development
of Efsubaglutide Alfa and a significant step forward in Innogen’s global expansion
strategy. It also highlights the potential for China-originated innovation to move
beyond domestic commercialization and reach international markets.

Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in
selected countries within Africa, Eastern Europe, Latin America, and the Middle 
East, while Innogen retains the relevant rights in the rest of the world. According
to the International Diabetes Federation (IDF), approximately 589 million adults
worldwide are living with diabetes, a figure projected to rise to 853 million by
2050. The World Health Organization (WHO) reports that more than one billion people
worldwide are living with obesity. As the health burden associated with diabetes,
obesity and related metabolic diseases continues to draw attention, demand for innovative
treatment options is becoming increasingly evident. Through this collaboration, 
the two companies will leverage their respective strengths in innovative drug development,
international regulatory affairs, market access and commercialization to advance
the development and commercialization of Efsubaglutide Alfa in the licensed territories
and expand local patients’ access to innovative treatment options.

Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an 
IgG Fc fragment. It has an average half-life of up to 280 hours across different
studies. Clinical studies have shown that monotherapy with Efsubaglutide Alfa reduced
HbA1c by 1.1 percentage points after four weeks, with a reduction of up to 2.2 percentage
points at Week 24, and that it may also help protect pancreatic beta-cell function.
Efsubaglutide Alfa has also shown promising clinical development potential in obesity
and related metabolic diseases. In the Phase IIb ENLIGHT study in Chinese adults
with overweight or obesity, participants receiving 20 mg once weekly (QW) for 18
weeks achieved an average body-weight reduction of 10.6% and a waist-circumference
reduction of approximately 8.9 cm. The group receiving 20 mg once every two weeks(
Q2W) achieved an average body-weight reduction of 9.7%.

The study also observed improvements in body-composition. The muscle-to-fat ratio
increased by up to 45.3% from baseline with QW dosing, with weight loss driven predominantly
by a reduction in fat mass, indicating fat reduction with relative preservation 
of muscle. Liver fat content was reduced by up to 51.8% with QW dosing. The incidence
of gastrointestinal adverse events were low relative to other GLP-1 receptor agonists(
based on cross-trial comparisons), no participants discontinued treatment due to
adverse events during the 18-week treatment period, and the treatment was well tolerated.
Innogen has also completed a Phase II clinical trial in adults with overweight or
obesity in Australia, evaluating the efficacy and safety of once-monthly (Q4W) dosing.
The study generated further clinical evidence to support the product’s future global
registration and commercialization.

**Dr. Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals
said: **"We are delighted to establish this collaboration with Arcera, which represents
an important step in Innogen’s international expansion. We believe that combining
world-class science with entrepreneurial innovation is key to improving patient 
care. Innogen’s mission is to provide best-in-class and first-in-class therapies
for people living with diabetes, obesity and other metabolic diseases worldwide.
Our collaboration with Arcera is an important step toward this vision. By combining
Innogen’s scientific innovation with Arcera’s strengths in international regulatory
affairs and commercialization, we aim to broaden access to differentiated therapies
and ultimately improve the quality of life of patients around the world."

**Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said:** "Cardiometabolic
diseases remain among the most pressing healthcare challenges in the markets we 
serve. Our agreement with Innogen accelerates the bridge we are building between
China and our international markets to bring innovative medicines to more patients
and strengthen our cardiometabolic portfolio. By combining our partners’ scientific
capabilities with Arcera’s regulatory expertise, market access and overall commercial
reach, we aim to turn innovation into meaningful impact for people living with chronic
disease."

**About Innogen Pharmaceuticals**

Founded in 2014, Innogen Pharmaceuticals (HKEX: 2591) is a biopharmaceutical company
focused on the research, development and industrialization of innovative medicines
for metabolic diseases. The Company has a wholly self-developed pipeline covering
indications including type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, metabolic
dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), supported
by global intellectual property rights and a global patent portfolio. Its core product,
Efsubaglutide Alfa, is a next-generation, human-derived, ultra-long-acting GLP-1
receptor agonist developed in-house. It has been approved for the treatment of T2D
in mainland China and Macao, China, and has been included in China’s National Reimbursement
Drug List (2025 Version). Development of the product received support under China’s
13th Five-Year Plan Major New Drug Innovation program. It has also received the 
First Prize of the Science and Technology Award of the Chinese Pharmaceutical Association
and the First Prize of the Science and Technology Award of the Shanghai Pharmaceutical
Association. Innogen has entered the stage of global development and regulatory 
registration, and its manufacturing facilities have obtained PIC/S GMP certification.
The Company is committed to providing better treatment options for patients worldwide.
For more information, please visit [www.innogenpharm.com](https://www.innogenpharm.com/).

**About Arcera Life Sciences**

Arcera Life Sciences is an international life sciences company headquartered in 
Abu Dhabi, United Arab Emirates. Arcera brings innovative and proven medicines to
patients in over 100 countries worldwide, with operations spanning Africa, Eurasia,
Latin America, and the Middle East. Arcera commercializes medicines and healthcare
products across multiple therapeutic areas, supported by manufacturing and packaging
capabilities in eight countries. To expand access to innovative therapies, Arcera
partners with leading pharmaceutical and biotech companies, ensuring supply resilience
and quality standards. Its portfolio comprises over 2,000 product presentations 
marketed under 300+ brands in more than 60 direct markets. To learn more about Arcera,
visit [www.arceralifesciences.com](https://www.arceralifesciences.com/).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion ](https://en.prnasia.com/story/archive/5102469_CN02469_0?rand=184833)
